Industry
152d agoEli Lilly Secures $2.75B AI Drug Deal
A landmark $2.75 billion agreement between Eli Lilly and Insilico Medicine will launch AI‑designed therapeutics worldwide. The pact gives the pharma giant access to the company’s in‑silico discovery platform, while Insilico receives a $115 million upfront payment and performance‑linked royalties.
The Signal
The deal signals a new era of data‑driven drug development across the global market.